Literature DB >> 7504021

Differential expression in rheumatoid synovium and synovial fluid of alpha 4 beta 7 integrin. A novel receptor for fibronectin and vascular cell adhesion molecule-1.

A I Lazarovits1, J Karsh.   

Abstract

T lymphocyte adhesion to vascular endothelium plays an important role in the immunopathogenesis of rheumatoid arthritis. The migration of T lymphocytes into the synovium is mediated by a variety of adhesion molecules, notably the integrins. We have prepared Act I, a murine mAb that identifies a novel integrin termed alpha 4 beta 7. The natural ligands for alpha 4 beta 7 are vascular cell adhesion molecule-1 and fibronectin; both molecules are up-regulated in the rheumatoid synovium. We investigated the expression of alpha 4 beta 7 in the three compartments of rheumatoid arthritis, the peripheral blood, synovial fluid, and synovial membrane, utilizing the FACS and immunoperoxidase microscopy of frozen tissues. The results of our experiments show a striking differential expression of alpha 4 beta 7 integrin in rheumatoid arthritis. Sixty-two percent of synovial membrane T cells expressed high density alpha 4 beta 7, in contrast to only 4.7% of synovial fluid and 9.1% of PBL. These data suggest that the expression of alpha 4 beta 7 integrin may provide a mechanism whereby certain T cells adhere to rheumatoid synovium while others remain in the synovial fluid. The augmented expression of alpha 4 beta 7 in the synovial membrane T cells may contribute to the development and perpetuation of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504021

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  The pathophysiologic role of alpha 4 integrins in vivo.

Authors:  R R Lobb; M E Hemler
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

2.  Third International Workshop on Reactive Arthritis. 23-26 September 1995, Berlin, Germany. Report and abstracts.

Authors:  G Kingsley; J Sieper
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

3.  Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis.

Authors:  A Dybwad; O Førre; M Sioud
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

4.  Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease.

Authors:  A C Issekutz; L Ayer; M Miyasaka; T B Issekutz
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

Review 5.  Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis.

Authors:  C Barbadillo; A G-Arroyo; C Salas; J Mulero; F Sánchez-Madrid; J L Andreu
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions.

Authors:  T W Kuijpers
Journal:  Springer Semin Immunopathol       Date:  1995

Review 7.  Extracellular matrix proteins, regulators of T-cell functions in healthy and diseased individuals.

Authors:  A Gorski; J W Kupiec-Weglinski
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

Review 8.  Molecular analysis of the physiological and pathophysiological role of alpha 4-integrins.

Authors:  G Kilger; B Holzmann
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

Review 9.  Modulation of autoimmune arthritis by environmental 'hygiene' and commensal microbiota.

Authors:  David Langan; Eugene Y Kim; Kamal D Moudgil
Journal:  Cell Immunol       Date:  2018-12-10       Impact factor: 4.868

10.  A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers.

Authors:  D Elewaut; F De Keyser; N De Wever; D Baeten; N Van Damme; G Verbruggen; C Cuvelier; E M Veys
Journal:  Ann Rheum Dis       Date:  1998-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.